Arcellx Stock Earns 82 Relative Strength Rating

Blockhead

2024-12-28

Arcellx (ACLX) stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 79 to 82.

↑ X

This Is How A New President Will Impact Fed Rate Cuts In 2025

See All Videos

NOW PLAYING This Is How A New President Will Impact Fed Rate Cuts In 2025

This exclusive rating from Investor's Business Daily identifies share price performance with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the last 52 weeks compares to all the other stocks in our database.

Decades of market research shows that the market's biggest winners typically have an 80 or higher RS Rating in the early stages of their moves.

Hone Your Stock-Picking Skills By Focusing On These Factors

Is Arcellx Stock A Buy?

Arcellx stock is now considered extended and out of buy range after clearing a 74.09 buy point in a fourth-stage cup with handle. See if the biotech stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.

The Calif.-based biotech company reported 0% earnings growth in the latest quarterly report, while sales growth came in at 74%.

Arcellx stock holds the No. 111 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals (CPRX), ADMA Biologics (ADMA) and Exelixis (EXEL) are among the top 5 highly rated stocks within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."

YOU MAY ALSO LIKE:

Learn How To Time The Market With IBD's ETF Market Strategy

Find Today's Best Growth Stocks To Watch With IBD 50

Find The Best Long-Term Investments With IBD Long-Term Leaders

How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2494352670"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2494352670\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2494352670?lang=zh_TW&edition=fundamental","thumbnail":"https://www.investors.com/wp-content/uploads/2017/05/IRU77-150x150.jpg","is_english":true,"pubTime":"2024-12-28 03:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2494352670","market":"us","top_or_hot":-1,"title":"Arcellx Stock Earns 82 Relative Strength Rating","media":"Blockhead","content":"<html><body><div>\n<p><b>Arcellx</b> (ACLX) stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 79 to 82.</p>\n<span>\n<span>\n<span jw-video-key=\"ULpM3j8K\" vid-authors=\"MEREDITH HEYMAN\" vid-cat=\"IBD Explains\" vid-date=\"12/17/2024\" vid-date-tmsp=\"1734424574\" vid-dom-id=\"9579501-676f3d3fc8c34\" vid-id=\"9579501\" vid-image=\"https://www.investors.com/wp-content/uploads/2024/12/ULpM3j8K-640x360.jpg\" vid-name=\"This Is How A New President Will Impact Fed Rate Cuts In 2025\" vid-repeat=\"1\" vid-top=\"\" vid-url=\"https://content.jwplatform.com/manifests/ULpM3j8K.m3u8\" vid-width=\"50\">\n<span>↑</span>\n<span>X</span>\n<span>\n<span></span>\n<div>\n<div>\nThis Is How A New President Will Impact Fed Rate Cuts In 2025\n</div>\n<div>\nSee All Videos\n</div>\n</div>\n</span>\n<span>\n<span>NOW PLAYING</span>\n<span>This Is How A New President Will Impact Fed Rate Cuts In 2025</span>\n</span>\n</span>\n</span>\n</span>\n<p>This exclusive rating from Investor's Business Daily identifies share price performance with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the last 52 weeks compares to all the other stocks in our database.</p>\n<p>Decades of market research shows that the market's biggest winners typically have an 80 or higher RS Rating in the early stages of their moves.</p>\n<hr/>\n<p>Hone Your Stock-Picking Skills By Focusing On These Factors</p>\n<hr/>\n<h2>Is Arcellx Stock A Buy?</h2>\n<p>Arcellx stock is now considered extended and out of buy range after clearing a 74.09 buy point in a fourth-stage cup with handle. See if the biotech stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.</p>\n<div><div></div></div>\n<p>The Calif.-based biotech company reported 0% earnings growth in the latest quarterly report, while sales growth came in at 74%.</p>\n<p>Arcellx stock holds the No. 111 rank among its peers in the Medical-Biomed/Biotech industry group. <b>Catalyst Pharmaceuticals</b> (CPRX), <b>ADMA Biologics</b> (ADMA) and <b>Exelixis</b> (EXEL) are among the top 5 highly rated stocks within the group. For more industry news, check out \"Biotech And Pharmaceutical Industry And Stock News.\"</p>\n<p><strong>YOU MAY ALSO LIKE:</strong></p>\n<p><span>Learn How To Time The Market With IBD's ETF Market Strategy</span></p>\n<p><span>Find Today's Best Growth Stocks To Watch With IBD 50</span></p>\n<p><span>Find The Best Long-Term Investments With IBD Long-Term Leaders</span></p>\n<p><span>How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks</span></p>\n</div></body></html>","source":"investor_business_daily_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Arcellx Stock Earns 82 Relative Strength Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArcellx Stock Earns 82 Relative Strength Rating\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Blockhead</strong><span class=\"h-time small\">2024-12-28 03:09</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><div>\n<p><b>Arcellx</b> (ACLX) stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 79 to 82.</p>\n<span>\n<span>\n<span jw-video-key=\"ULpM3j8K\" vid-authors=\"MEREDITH HEYMAN\" vid-cat=\"IBD Explains\" vid-date=\"12/17/2024\" vid-date-tmsp=\"1734424574\" vid-dom-id=\"9579501-676f3d3fc8c34\" vid-id=\"9579501\" vid-image=\"https://www.investors.com/wp-content/uploads/2024/12/ULpM3j8K-640x360.jpg\" vid-name=\"This Is How A New President Will Impact Fed Rate Cuts In 2025\" vid-repeat=\"1\" vid-top=\"\" vid-url=\"https://content.jwplatform.com/manifests/ULpM3j8K.m3u8\" vid-width=\"50\">\n<span>↑</span>\n<span>X</span>\n<span>\n<span></span>\n<div>\n<div>\nThis Is How A New President Will Impact Fed Rate Cuts In 2025\n</div>\n<div>\nSee All Videos\n</div>\n</div>\n</span>\n<span>\n<span>NOW PLAYING</span>\n<span>This Is How A New President Will Impact Fed Rate Cuts In 2025</span>\n</span>\n</span>\n</span>\n</span>\n<p>This exclusive rating from Investor's Business Daily identifies share price performance with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the last 52 weeks compares to all the other stocks in our database.</p>\n<p>Decades of market research shows that the market's biggest winners typically have an 80 or higher RS Rating in the early stages of their moves.</p>\n<hr/>\n<p>Hone Your Stock-Picking Skills By Focusing On These Factors</p>\n<hr/>\n<h2>Is Arcellx Stock A Buy?</h2>\n<p>Arcellx stock is now considered extended and out of buy range after clearing a 74.09 buy point in a fourth-stage cup with handle. See if the biotech stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.</p>\n<div><div></div></div>\n<p>The Calif.-based biotech company reported 0% earnings growth in the latest quarterly report, while sales growth came in at 74%.</p>\n<p>Arcellx stock holds the No. 111 rank among its peers in the Medical-Biomed/Biotech industry group. <b>Catalyst Pharmaceuticals</b> (CPRX), <b>ADMA Biologics</b> (ADMA) and <b>Exelixis</b> (EXEL) are among the top 5 highly rated stocks within the group. For more industry news, check out \"Biotech And Pharmaceutical Industry And Stock News.\"</p>\n<p><strong>YOU MAY ALSO LIKE:</strong></p>\n<p><span>Learn How To Time The Market With IBD's ETF Market Strategy</span></p>\n<p><span>Find Today's Best Growth Stocks To Watch With IBD 50</span></p>\n<p><span>Find The Best Long-Term Investments With IBD Long-Term Leaders</span></p>\n<p><span>How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks</span></p>\n</div></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://www.investors.com/news/arcellx-stock-earns-82-relative-strength-rating/\">Blockhead</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RS","symbol_name":"Reliance Steel & Aluminum Co","start_time":0,"source_url":"https://www.investors.com/news/arcellx-stock-earns-82-relative-strength-rating/","article_id":"2494352670","we_media_id":null,"thumbnails":["https://www.investors.com/wp-content/uploads/2017/05/IRU77-150x150.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2494352670","pubTimestamp":1735326540,"columns":[],"sourceInfo":{"source_id":"investor_business_daily_highlight","name":"Investor’s Business Daily"},"weMediaInfo":null,"summary":"Arcellx shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 82.","collect":0,"end_time":0,"defaultTopTitle":"investors.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"RS":"Reliance Steel & Aluminum Co","EXEL":"伊克力西斯","BK4532":"文艺复兴科技持仓","BK4006":"钢铁","BK4139":"生物科技","ADMA":"ADMA Biologics Inc","CPRX":"Catalyst Pharmaceutical Partners","ACLX":"ARCELLX, INC."},"translate_title":"Arcellx股票获得82相对强度评级","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACLX":1,"ADMA":1,"CPRX":1,"EXEL":1,"RS":1},"content_text":"Arcellx (ACLX) stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 79 to 82.\n\n\n\n↑\nX\n\n\n\n\nThis Is How A New President Will Impact Fed Rate Cuts In 2025\n\n\nSee All Videos\n\n\n\n\nNOW PLAYING\nThis Is How A New President Will Impact Fed Rate Cuts In 2025\n\n\n\n\nThis exclusive rating from Investor's Business Daily identifies share price performance with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the last 52 weeks compares to all the other stocks in our database.\nDecades of market research shows that the market's biggest winners typically have an 80 or higher RS Rating in the early stages of their moves.\n\nHone Your Stock-Picking Skills By Focusing On These Factors\n\nIs Arcellx Stock A Buy?\nArcellx stock is now considered extended and out of buy range after clearing a 74.09 buy point in a fourth-stage cup with handle. See if the biotech stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.\n\nThe Calif.-based biotech company reported 0% earnings growth in the latest quarterly report, while sales growth came in at 74%.\nArcellx stock holds the No. 111 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals (CPRX), ADMA Biologics (ADMA) and Exelixis (EXEL) are among the top 5 highly rated stocks within the group. For more industry news, check out \"Biotech And Pharmaceutical Industry And Stock News.\"\nYOU MAY ALSO LIKE:\nLearn How To Time The Market With IBD's ETF Market Strategy\nFind Today's Best Growth Stocks To Watch With IBD 50\nFind The Best Long-Term Investments With IBD Long-Term Leaders\nHow To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}